Crohn's Disease (Regional Enteritis) - Pipeline Review, H1 2020
Crohn's Disease (Regional Enteritis) - Pipeline Review, H1 2020
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Crohn's Disease - Pipeline Review, H1 2020, provides an overview of the Crohn's Disease (Gastrointestinal) pipeline landscape.
Crohn’s disease is an inflammatory bowel disease (IBD). It causes inflammation of the lining of digestive tract, which can lead to abdominal pain, severe diarrhea and even malnutrition. Inflammation caused by Crohn’s disease can involve different areas of the digestive tract in different people. Signs and symptoms may include diarrhea, abdominal pain and cramping, blood in stool, ulcers, reduced appetite and weight loss. Risk factor include age, family history, smoking and use of Non-steroidal anti-inflammatory medications.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Crohn's Disease - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Crohn's Disease (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Crohn's Disease (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Crohn's Disease (Regional Enteritis) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 15, 36, 30, 1, 70, 19 and 1 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 3 and 2 molecules, respectively.
Crohn's Disease (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Crohn's Disease - Pipeline Review, H1 2020, provides an overview of the Crohn's Disease (Gastrointestinal) pipeline landscape.
Crohn’s disease is an inflammatory bowel disease (IBD). It causes inflammation of the lining of digestive tract, which can lead to abdominal pain, severe diarrhea and even malnutrition. Inflammation caused by Crohn’s disease can involve different areas of the digestive tract in different people. Signs and symptoms may include diarrhea, abdominal pain and cramping, blood in stool, ulcers, reduced appetite and weight loss. Risk factor include age, family history, smoking and use of Non-steroidal anti-inflammatory medications.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Crohn's Disease - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Crohn's Disease (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Crohn's Disease (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Crohn's Disease (Regional Enteritis) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 15, 36, 30, 1, 70, 19 and 1 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 3 and 2 molecules, respectively.
Crohn's Disease (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The pipeline guide provides a snapshot of the global therapeutic landscape of Crohn's Disease (Gastrointestinal).
- The pipeline guide reviews pipeline therapeutics for Crohn's Disease (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Crohn's Disease (Gastrointestinal) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Crohn's Disease (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Crohn's Disease (Gastrointestinal)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Crohn's Disease (Gastrointestinal).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Crohn's Disease (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Crohn's Disease (Regional Enteritis) - Overview
Crohn's Disease (Regional Enteritis) - Therapeutics Development
Crohn's Disease (Regional Enteritis) - Therapeutics Assessment
Crohn's Disease (Regional Enteritis) - Companies Involved in Therapeutics Development
Crohn's Disease (Regional Enteritis) - Drug Profiles
Crohn's Disease (Regional Enteritis) - Dormant Projects
Crohn's Disease (Regional Enteritis) - Discontinued Products
Crohn's Disease (Regional Enteritis) - Product Development Milestones
Appendix
Crohn's Disease (Regional Enteritis) - Overview
Crohn's Disease (Regional Enteritis) - Therapeutics Development
Crohn's Disease (Regional Enteritis) - Therapeutics Assessment
Crohn's Disease (Regional Enteritis) - Companies Involved in Therapeutics Development
Crohn's Disease (Regional Enteritis) - Drug Profiles
Crohn's Disease (Regional Enteritis) - Dormant Projects
Crohn's Disease (Regional Enteritis) - Discontinued Products
Crohn's Disease (Regional Enteritis) - Product Development Milestones
Appendix
LIST OF TABLES
Number of Products under Development for Crohn's Disease (Regional Enteritis), H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..2), H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..3), H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..4), H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..5), H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..6), H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Companies, H1 2020 (Contd..2), H1 2020
Products under Development by Companies, H1 2020 (Contd..3), H1 2020
Products under Development by Companies, H1 2020 (Contd..4), H1 2020
Products under Development by Companies, H1 2020 (Contd..5), H1 2020
Products under Development by Companies, H1 2020 (Contd..6), H1 2020
Products under Development by Companies, H1 2020 (Contd..7), H1 2020
Products under Development by Companies, H1 2020 (Contd..8), H1 2020
Products under Development by Companies, H1 2020 (Contd..9), H1 2020
Products under Development by Companies, H1 2020 (Contd..10), H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Target, H1 2020 (Contd..1), H1 2020
Number of Products by Stage and Target, H1 2020 (Contd..2), H1 2020
Number of Products by Stage and Target, H1 2020 (Contd..3), H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..1), H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..2), H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..3), H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Crohn's Disease (Regional Enteritis) - Pipeline by 4D Pharma Plc, H1 2020
Crohn's Disease (Regional Enteritis) - Pipeline by AbbVie Inc, H1 2020
Crohn's Disease (Regional Enteritis) - Pipeline by Abivax SA, H1 2020
Crohn's Disease (Regional Enteritis) - Pipeline by Aclaris Therapeutics Inc, H1 2020
Crohn's Disease (Regional Enteritis) - Pipeline by Active Biotech AB, H1 2020
Crohn's Disease (Regional Enteritis) - Dormant Projects, H1 2020
Crohn's Disease (Regional Enteritis) - Discontinued Products, H1 2020
Crohn's Disease (Regional Enteritis) - Discontinued Products, H1 2020 (Contd..1), H1 2020
Number of Products under Development for Crohn's Disease (Regional Enteritis), H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..2), H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..3), H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..4), H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..5), H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..6), H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Companies, H1 2020 (Contd..2), H1 2020
Products under Development by Companies, H1 2020 (Contd..3), H1 2020
Products under Development by Companies, H1 2020 (Contd..4), H1 2020
Products under Development by Companies, H1 2020 (Contd..5), H1 2020
Products under Development by Companies, H1 2020 (Contd..6), H1 2020
Products under Development by Companies, H1 2020 (Contd..7), H1 2020
Products under Development by Companies, H1 2020 (Contd..8), H1 2020
Products under Development by Companies, H1 2020 (Contd..9), H1 2020
Products under Development by Companies, H1 2020 (Contd..10), H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Target, H1 2020 (Contd..1), H1 2020
Number of Products by Stage and Target, H1 2020 (Contd..2), H1 2020
Number of Products by Stage and Target, H1 2020 (Contd..3), H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..1), H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..2), H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..3), H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Crohn's Disease (Regional Enteritis) - Pipeline by 4D Pharma Plc, H1 2020
Crohn's Disease (Regional Enteritis) - Pipeline by AbbVie Inc, H1 2020
Crohn's Disease (Regional Enteritis) - Pipeline by Abivax SA, H1 2020
Crohn's Disease (Regional Enteritis) - Pipeline by Aclaris Therapeutics Inc, H1 2020
Crohn's Disease (Regional Enteritis) - Pipeline by Active Biotech AB, H1 2020
Crohn's Disease (Regional Enteritis) - Dormant Projects, H1 2020
Crohn's Disease (Regional Enteritis) - Discontinued Products, H1 2020
Crohn's Disease (Regional Enteritis) - Discontinued Products, H1 2020 (Contd..1), H1 2020
LIST OF FIGURES
Number of Products under Development for Crohn's Disease (Regional Enteritis), H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Top 10 Routes of Administration, H1 2020
Number of Products by Stage and Top 10 Routes of Administration, H1 2020
Number of Products by Top 10 Molecule Types, H1 2020
Number of Products by Stage and Top 10 Molecule Types, H1 2020
COMPANIES MENTIONED
4D Pharma Plc
AbbVie Inc
Abivax SA
Aclaris Therapeutics Inc
Active Biotech AB
Affilogic SAS
Aibios Co Ltd
Akeso Biopharma Inc
AlfaSigma SpA
Algernon Pharmaceuticals Inc
Allergan Plc
Alpha Cancer Technologies Inc
Alvotech ehf
Amgen Inc
Anterogen Co Ltd
Antibe Therapeutics Inc
Arena Pharmaceuticals Inc
Artelo Biosciences Inc
Artizan Biosciences Inc
Asdera LLC
Atlantic Bio Sci LLC
Atlantic Healthcare Plc
Avexegen Therapeutics Inc
Avobis Bio
Axim Biotechnologies Inc
Baylx Inc
BioLingus AG
Biond Biologics Ltd
BioXpress Therapeutics SA
Boehringer Ingelheim International GmbH
Bristol-Myers Squibb Co
Celltrion Inc
Celularity Inc
ChemoCentryx Inc
Chong Kun Dang Pharmaceutical Corp
Commence Bio Inc
Cytocom Inc
Daiichi Sankyo Co Ltd
DBV Technologies SA
Defensin Therapeutics ApS
Denali Therapeutics Inc
DM Bio Ltd
DNX Biopharmaceuticals Inc
EA Pharma Co Ltd
Eisai Co Ltd
Eli Lilly and Co
Enterome Bioscience SA
Enzo Biochem Inc
ETX Pharma Inc
ExCellThera Inc
Exeliom Biosciences SAS
Ferring International Center SA
Fimbrion Therapeutics Inc
Finch Therapeutics Group
Fujifilm Kyowa Kirin Biologics Co Ltd
FYB202 GmbH & Co KG
Galactica Biotech Ltd
Galapagos NV
Genentech Inc
GlaxoSmithKline Plc
Gossamer Bio Inc
HAV Vaccines Ltd
Immunic Inc
Inception Sciences Inc
InDex Pharmaceuticals Holding AB
InflammatoRx inc
Innovate Biopharmaceuticals Inc
Innovation Pharmaceuticals Inc
Innovent Biologics Inc
Innovimmune Biotherapeutics Inc
InSight Biopharmaceuticals Ltd
Inspyr Therapeutics Inc
Intract Pharma Ltd
JHL Biotech Inc
Jiangsu Hengrui Medicine Co Ltd
Johnson & Johnson
Jyant Technologies Inc
Kang Stem Biotech Co Ltd
Koutif Therapeutics LLC
Kyowa Kirin Co Ltd
Landos Biopharma Inc
Locus Biosciences Inc
Machavert Pharmaceuticals LLC
Macrophage Therapeutics Inc
MAKScientific LLC
Menemsha Pharmaceuticals Ltd
Mesoblast Ltd
Metacrine Inc
MetiMedi Pharmaceuticals Co Ltd
MGC Pharmaceuticals Ltd
Mitsubishi Tanabe Pharma Corp
Morphic Holding Inc
Mycenax Biotech Inc
Naia Rare Diseases Inc
NeuClone Pty Ltd
Nichi-Iko Pharmaceutical Co Ltd
Nimbus Therapeutics LLC
Oncodesign SA
OSE Immunotherapeutics
Otsuka Holdings Co Ltd
PanTheryx Inc
Par'Immune SAS
Paradigm Biopharmaceuticals Ltd
Pfizer Inc
Pharmapraxis
Polpharma Biologics
Praeventix LLC
Protagonist Therapeutics Inc
Protheragen Inc
Qu Biologics Inc
Re-Pharm Ltd
Rebiotix Inc
RedHill Biopharma Ltd
Redx Pharma Plc
Regentys Corp
Reponex Pharmaceuticals Aps
Saje Pharma LLC
Saniona AB
Semorex Technologies Ltd
Seres Therapeutics Inc
Siam Bioscience Co Ltd
Soligenix Inc
STERO Biotechs Ltd
Suzhou Connect Biopharmaceuticals Ltd
Synedgen Inc
Synlogic Inc
TaiwanJ Pharmaceuticals Co Ltd
Takeda Pharmaceutical Co Ltd
Temisis Therapeutics
Tetherex Pharmaceuticals Corp
The Cell Factory BVBA
Theravance Biopharma Inc
Thetis Pharmaceuticals LLC
Tiziana Life Sciences Plc
TRACT Therapeutics Inc
Trio Medicines Ltd
Ventria Bioscience
VHsquared Ltd
Winston Pharmaceuticals Inc
XBiotech Inc
Xbrane Biopharma AB
Yom Chai
Number of Products under Development for Crohn's Disease (Regional Enteritis), H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Top 10 Routes of Administration, H1 2020
Number of Products by Stage and Top 10 Routes of Administration, H1 2020
Number of Products by Top 10 Molecule Types, H1 2020
Number of Products by Stage and Top 10 Molecule Types, H1 2020
COMPANIES MENTIONED
4D Pharma Plc
AbbVie Inc
Abivax SA
Aclaris Therapeutics Inc
Active Biotech AB
Affilogic SAS
Aibios Co Ltd
Akeso Biopharma Inc
AlfaSigma SpA
Algernon Pharmaceuticals Inc
Allergan Plc
Alpha Cancer Technologies Inc
Alvotech ehf
Amgen Inc
Anterogen Co Ltd
Antibe Therapeutics Inc
Arena Pharmaceuticals Inc
Artelo Biosciences Inc
Artizan Biosciences Inc
Asdera LLC
Atlantic Bio Sci LLC
Atlantic Healthcare Plc
Avexegen Therapeutics Inc
Avobis Bio
Axim Biotechnologies Inc
Baylx Inc
BioLingus AG
Biond Biologics Ltd
BioXpress Therapeutics SA
Boehringer Ingelheim International GmbH
Bristol-Myers Squibb Co
Celltrion Inc
Celularity Inc
ChemoCentryx Inc
Chong Kun Dang Pharmaceutical Corp
Commence Bio Inc
Cytocom Inc
Daiichi Sankyo Co Ltd
DBV Technologies SA
Defensin Therapeutics ApS
Denali Therapeutics Inc
DM Bio Ltd
DNX Biopharmaceuticals Inc
EA Pharma Co Ltd
Eisai Co Ltd
Eli Lilly and Co
Enterome Bioscience SA
Enzo Biochem Inc
ETX Pharma Inc
ExCellThera Inc
Exeliom Biosciences SAS
Ferring International Center SA
Fimbrion Therapeutics Inc
Finch Therapeutics Group
Fujifilm Kyowa Kirin Biologics Co Ltd
FYB202 GmbH & Co KG
Galactica Biotech Ltd
Galapagos NV
Genentech Inc
GlaxoSmithKline Plc
Gossamer Bio Inc
HAV Vaccines Ltd
Immunic Inc
Inception Sciences Inc
InDex Pharmaceuticals Holding AB
InflammatoRx inc
Innovate Biopharmaceuticals Inc
Innovation Pharmaceuticals Inc
Innovent Biologics Inc
Innovimmune Biotherapeutics Inc
InSight Biopharmaceuticals Ltd
Inspyr Therapeutics Inc
Intract Pharma Ltd
JHL Biotech Inc
Jiangsu Hengrui Medicine Co Ltd
Johnson & Johnson
Jyant Technologies Inc
Kang Stem Biotech Co Ltd
Koutif Therapeutics LLC
Kyowa Kirin Co Ltd
Landos Biopharma Inc
Locus Biosciences Inc
Machavert Pharmaceuticals LLC
Macrophage Therapeutics Inc
MAKScientific LLC
Menemsha Pharmaceuticals Ltd
Mesoblast Ltd
Metacrine Inc
MetiMedi Pharmaceuticals Co Ltd
MGC Pharmaceuticals Ltd
Mitsubishi Tanabe Pharma Corp
Morphic Holding Inc
Mycenax Biotech Inc
Naia Rare Diseases Inc
NeuClone Pty Ltd
Nichi-Iko Pharmaceutical Co Ltd
Nimbus Therapeutics LLC
Oncodesign SA
OSE Immunotherapeutics
Otsuka Holdings Co Ltd
PanTheryx Inc
Par'Immune SAS
Paradigm Biopharmaceuticals Ltd
Pfizer Inc
Pharmapraxis
Polpharma Biologics
Praeventix LLC
Protagonist Therapeutics Inc
Protheragen Inc
Qu Biologics Inc
Re-Pharm Ltd
Rebiotix Inc
RedHill Biopharma Ltd
Redx Pharma Plc
Regentys Corp
Reponex Pharmaceuticals Aps
Saje Pharma LLC
Saniona AB
Semorex Technologies Ltd
Seres Therapeutics Inc
Siam Bioscience Co Ltd
Soligenix Inc
STERO Biotechs Ltd
Suzhou Connect Biopharmaceuticals Ltd
Synedgen Inc
Synlogic Inc
TaiwanJ Pharmaceuticals Co Ltd
Takeda Pharmaceutical Co Ltd
Temisis Therapeutics
Tetherex Pharmaceuticals Corp
The Cell Factory BVBA
Theravance Biopharma Inc
Thetis Pharmaceuticals LLC
Tiziana Life Sciences Plc
TRACT Therapeutics Inc
Trio Medicines Ltd
Ventria Bioscience
VHsquared Ltd
Winston Pharmaceuticals Inc
XBiotech Inc
Xbrane Biopharma AB
Yom Chai
